Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Tattelecom recommended that dividends be paid for 2022

3/7/23 TTLK

Court approves amicable settlement of EL5-Energo's claim against Siemens Gamesa

3/7/23 ELFV

On VK Video there will be a premiere of STS series based on the script of a neural network

3/7/23 VKCO

An alternative to the Medsi IPO could be a strategic partnership through a share swap

3/7/23 AFKS

Russian legal entity VK bought out 100% of Dengi.Mail.Ru

3/7/23 VKCO

Positive Technologies shareholders to discuss Q1 202 dividend on April 05

3/6/23 POSI

Lukoil Approved for Commercialization of Reserves in Iraq

3/6/23 LKOH

Inter RAO reported for 2022 according to RAS

3/6/23 IRAO

Moscow Exchange's Supervisory Board will discuss tomorrow the AGM's recommendation on dividends for 2022

3/6/23 MOEX

Positive Technologies disclosed management metrics and gave a dividend benchmark

3/6/23 POSI